Wynn Resorts 3Q25 Earnings Presentation November 2025 1 Forward-Looking Statements This presentation contains forward-looking statements regarding operating trends and future results of operations. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those we express in these forward-looking statements, including, but not limited to, reductions in discretionary consumer spending, adverse macroeconomic conditions and thei ...

Financial Performance - Q3 2025 revenue reached $4.1 million[6,21] - The company holds approximately $251 million in cash, cash equivalents, and investments[6,21] - Gross margin for Q3 2025 was 51%, compared to 48% in Q3 2024[21] - Net loss for Q3 2025 was $18.2 million, an improvement from the $21.3 million net loss in Q3 2024[21] - The company repurchased approximately 1 million shares in Q3, bringing the total to approximately 11.7 million shares, reducing net total shares outstanding by approximately 14%[22] - The company reiterates full year 2025 revenue guidance of $17 million to $18 million, representing 24% year-over-year growth at the midpoint[23] Product and Platform Adoption - The company delivered the third consecutive quarter of strong instrument shipments[7] - The Proteograph ONE workflow doubles throughput to 80 samples per run, with an approximate 30% reduction in run time to approximately 4.5 hours compared to Proteograph XT[11] - The Proteograph ONE workflow can analyze over 1,000 samples per week[11] - The company shipped nearly three times as many instruments in the first nine months of 2025 as in all of 2024[20]

TAKE-TWO INTERACTIVE SOFTWARE, INC. (NASDAQ: TTWO) SECOND QUARTER FISCAL 2026 RESULTS & GUIDANCE SUMMARY CAUTIONARY NOTE: FORWARD LOOKING STATEMENTS The statements contained herein, which are not historical facts, including statements relating to Take-Two Interactive Software, Inc.'s ("Take-Two," the "Company," "we," "us," or similar pronouns) outlook, are considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expec ...

Financial Performance - Q3 2025 revenue was $17.1 million, a 13% decrease compared to $19.5 million in Q3 2024[13] - Operating expenses decreased by 24%, from $30.2 million in Q3 2024 to $23.0 million in Q3 2025[13] - Net loss improved by 18.5%, decreasing from $16.2 million in Q3 2024 to $13.2 million in Q3 2025[13] - Net cash use improved to $6.2 million in Q3 compared to $10.1 million in Q2[14] - The company raised $13.8 million through a private placement in August[16] Gross Margin - Gross margin was 81.3% in Q3 2025, a decrease of 240 bps compared to 83.7% in Q3 2024, while RECELL-only gross margin was 83.6% for the quarter[13] Market and Strategy - The company is focusing on approximately 200 key burn and trauma centers[11, 12] - The U S total addressable market (TAM) is estimated to be over $3.5 billion[11] - The company is active in approximately 90% of target sites, representing a $1.3 billion U S total addressable market, and currently serves approximately 5% of this TAM[12] Reimbursement - All seven Medicare Administrative Contractors (MACs) have published or confirmed payment rates for RECELL[7]

Financial Performance - Total revenue and non-GAAP operating income for Q3 2025 exceeded guidance[6] - Consumer Banking Suite revenue increased by 34% year-over-year[7] - Non-GAAP operating expenses reflect cost discipline[17] - Q4 2025 total revenue is expected to be between $31 million and $32.5 million, representing a year-over-year increase of 5% at the midpoint[26] - Non-GAAP net income from continuing operations was $5560 thousand for Q3 2025, compared to a loss of $631 thousand in GAAP[35] Revenue Breakdown - Consumer Banking Suite revenue was $12724 thousand in Q3 2025, a 34% increase year-over-year[29] - Mortgage Suite revenue was $17735 thousand in Q3 2025, an 18% decrease year-over-year[29] - Total Software Platform revenue was $30459 thousand in Q3 2025, a 2% decrease year-over-year[29] Market Position - Blend's funded loans as a percentage of HMDA mortgage originations is estimated to be 16-18% in 2025[23] - The company's market share has decreased since 2023 due to churn notices received primarily in 2023 and 2024[24] - Added or expanded 14 customer relationships this quarter, with pipeline up approximately 60% year-over-year[6]

Atacicept Clinical Development & Regulatory Milestones - Vera Therapeutics anticipates a US market launch of atacicept for IgAN in 2026, pending FDA approval[8, 9] - Phase 3 ORIGIN trial of atacicept achieved its primary endpoint, demonstrating a statistically significant 42% reduction in proteinuria (UPCR) compared to placebo at week 36 (p<00001)[43] - In the ORIGIN 3 trial, atacicept showed a 67% reduction in Gd-IgA1 and an 81% resolution of hematuria compared to placebo[48] - Vera Therapeutics plans to submit a BLA for atacicept in Q4 2025[8] Financial Position - As of September 30, 2025, Vera Therapeutics has approximately $497 million in cash, cash equivalents, and marketable securities[11] - Vera Therapeutics has an additional $425 million in non-dilutive capital available through the Oxford Facility[12] IgAN Market & Atacicept Potential - Vera Therapeutics estimates the US IgAN prevalence to be approximately 004% of the US population, or about 160,000 patients[59] - Nephrologists ranked atacicept as the most desired IgAN pipeline agent, with 30% considering it the most desired and 73% ranking it in the top 3[62] Pipeline Expansion - Vera Therapeutics is conducting a Phase 2 PIONEER trial to evaluate atacicept in expanded IgAN populations and anti-PLA2R & anti-nephrin podocytopathies[81]

Financial Performance & Growth - Total member growth reached 53%, increasing from 543,000 in Q3 2024 to 831,000 in Q3 2025[14] - Revenue grew by 49%, from $455 million in Q3 2024 to $680 million in Q3 2025[14] - Non-GAAP Gross Profit increased by 56%, from $297 million in Q3 2024 to $464 million in Q3 2025, with Gross Margins at 652% and 682% respectively[14] - Net loss improved by $6 million, decreasing from $(92) million in Q3 2024 to $(32) million in Q3 2025[14] - Adjusted EBITDA grew by $75 million, increasing from $(51) million in Q3 2024 to $24 million in Q3 2025[14] Business Model & Customer Base - The company has over 2,000 customers[16, 134] and a customer retention rate of over 90%[16, 134] - Over 20 million individuals have benefits coverage for one or more programs[16, 80] - The company's revenue model is recurring, tied to member success, and billable through payer claims for certain customers[16, 18] Market Opportunity & GLP-1 Strategy - The total current addressable market is estimated at $414 billion for prediabetes, $173 billion for diabetes, $316 billion for hypertension, and $448 billion for musculoskeletal conditions[24] - Enhanced GLP-1 Care Track members experienced 28% greater weight loss compared to members not enrolled in the track over the first 16 weeks[101] - Enhanced GLP-1 Care Track members maintained weight loss at 16 weeks post-discontinuation, with an average weight change of 08%[100, 101]

Third Quarter Earnings Conference Call November 6, 2025 Foward Looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of, and subject to the protection of, the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 ...

Financial Performance - Revenue for 3Q 2025 was $253 million, including $253 million from milestones and research period extension fees from J&J and Merck, and $1 million in royalty revenues from Jazz and BeOne[17,18] - Cash, cash equivalents, and marketable securities totaled $3242 million as of 3Q 2025[17] - Completed share repurchases of $227 million of the remaining $30 million share repurchase program for 1439068 shares at an average price of $1580 per share[15] - R&D expenses were slightly decreased due to program mix and timing, partially offset by higher stock-based compensation expense[18] Pipeline Progress - Preliminary Phase 1 data on ZW191 provides early validation of ADC platform[15] - First patient dosed in Phase 1 clinical trial of ZW251, a DAR4 ADC targeting GPC3[15] - Partner Jazz presented a trial-in-progress poster on the DiscovHER PAN-206 phase 2 study of zanidatamab in HER2-overexpressing solid tumors, as well as a two-year follow-up in first-line mCRC at EMSO[15] - J&J Innovative Medicine initiated Phase 3 study for pasritamig (JNJ-78278343) triggering $25 million development milestone[15] ZW191 Clinical Data - ZW191 demonstrated a favorable clinical safety profile, with an any TRAE rate of 80% (33 out of 41 participants) and a Grade ≥3 TRAE rate of 17% (7 out of 41 participants)[20] - Preliminary efficacy data for response-evaluable participants with gynecological cancer showed a PR rate of 50% (12 out of 24 participants)[25] - Randomized dose optimization to begin in 4Q-2025 in platinum resistant ovarian cancer at 96 and 64 mg/kg doses (~30 pts/cohort)[27] Strategic Outlook - Diverse potential revenue streams from existing partnerships, with potential future milestone payments of up to $136 billion for zanidatamab-hrii and up to $434 million for JNJ-78278343[39] - Near-term revenue catalysts include continued royalties from Jazz and BeOne Medicines for Ziihera® expected in 2025[40]

Q3 Supplemental Information NOVEMBER 2025 Funko, LLC © 2025 Cautionary Notes This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our future results of operations and financial position, industry dynamics, business strategy and plans and our objectives for fut ...